Cencora, Inc. Files 8-K on Financials
Ticker: COR · Form: 8-K · Filed: Nov 5, 2025 · CIK: 1140859
Sentiment: neutral
Topics: financial-reporting, results-of-operations
TL;DR
Cencora dropped its 8-K, check the financials.
AI Summary
Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. Cencora, Inc. is incorporated in Delaware and its fiscal year ends on September 30.
Why It Matters
This filing provides an update on Cencora's financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate material events indicated.
Key Players & Entities
- Cencora, Inc. (company) — Registrant
- AmerisourceBergen Corp (company) — Former company name
- November 5, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 23-3079390 (identifier) — IRS Employer Identification Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cencora, Inc.'s results of operations and financial condition, as well as to include Regulation FD disclosures and financial statements.
When was Cencora, Inc. formerly known as?
Cencora, Inc. was formerly known as AmerisourceBergen Corp.
In which state is Cencora, Inc. incorporated?
Cencora, Inc. is incorporated in Delaware.
What is the fiscal year end for Cencora, Inc.?
The fiscal year end for Cencora, Inc. is September 30.
What is the Commission File Number for Cencora, Inc.?
The Commission File Number for Cencora, Inc. is 1-16671.
Filing Stats: 871 words · 3 min read · ~3 pages · Grade level 9.8 · Accepted 2025-11-05 06:33:58
Filing Documents
- abc-20251105.htm (8-K) — 38KB
- exhibit991-q42025.htm (EX-99.1) — 655KB
- exhibit992.htm (EX-99.2) — 123KB
- abcpress.jpg (GRAPHIC) — 10KB
- logo.gif (GRAPHIC) — 4KB
- 0001140859-25-000128.txt ( ) — 1044KB
- abc-20251105.xsd (EX-101.SCH) — 3KB
- abc-20251105_def.xml (EX-101.DEF) — 16KB
- abc-20251105_lab.xml (EX-101.LAB) — 28KB
- abc-20251105_pre.xml (EX-101.PRE) — 16KB
- abc-20251105_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. Earnings Release for the Fiscal Quarter and Year Ended September 30, 2025 On November 5, 2025, Cencora, Inc. (the "Company") issued a news release announcing the Company's earnings for the fiscal quarter and year ended September 30, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. New Reporting Structure Recently, Cencora undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers. As a result of this review, the Company has reorganized certain business components within its reporting structure. Beginning in the first quarter of fiscal 2026, the Company's reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment will consist of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex. In the attached Exhibit 99.2, which is incorporated herein by reference, the Company is voluntarily furnishing a supplemental disclosure of unaudited revised reportable segment information for each of the quarters of fiscal 2025 and 2024 and the fiscal years ended September 30, 2025 and 2024 under the reporting structure that is expected to be utilized in fiscal 2026 to assist investors in analyzing the changes to its reporting structure. The information in this Current Report, including the exhibits attached hereto as Exhibit 99.1 and Exhibit 99.2 and the information under Item 7.01 below, is being
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 5, 2025, the Company is conducting a conference call and webcast scheduled to be held at 8:30 a.m. Eastern time regarding its results for the fiscal quarter and year ended September 30, 2025 and related matters. A link to the conference call and slides prepared for the conference call are available on the Company's website at investor.cencora.com.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 News Release of Cencora, Inc. dated November 5, 2025. 99.2 Unaudited revised reportable segment information for each of the quarters of fiscal 2025 and 2024 and the fiscal years ended September 30, 2025 and 2024 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cencora, Inc. Date: November 5, 2025 By: /s/ James F. Cleary Name: James F. Cleary Title: Executive Vice President & Chief Financial Officer